5.1 Neonatal RDS Pathophysiology & Management

5.1 Neonatal RDS Pathophysiology & Management

Neonatal respiratory distress in the immediate post-delivery transition is the leading cause of admission to the Neonatal Intensive Care Unit (NICU). For the neonatal and pediatric respiratory care specialist, rapid differentiation between primary surfactant deficiency (Respiratory Distress Syndrome) and delayed clearance of fetal lung liquid (Transient Tachypnea of the Newborn) is critical to deploying life-preserving noninvasive and surfactant therapies while avoiding unnecessary invasive interventions.

---

Respiratory Distress Syndrome (RDS / Hyaline Membrane Disease)

Respiratory Distress Syndrome (historically designated Hyaline Membrane Disease) is an acute restrictive pulmonary disorder seen predominantly in premature neonates, caused by developmental deficiency in surfactant production and release.

Biophysical Mechanics & The Law of Laplace

Pulmonary surfactant is synthesized, packaged into lamellar bodies, and secreted via exocytosis by alveolar type II pneumocytes beginning between 24 and 28 weeks gestation, with production accelerating markedly after 34 to 35 weeks.

Surfactant is an amphipathic lipoprotein complex comprised of:

• Phospholipids (~80%): Predominantly Dipalmitoylphosphatidylcholine (DPPC), also known as disaturated phosphatidylcholine, which lines the alveolar air-liquid interface to lower surface tension.
• Neutral Lipids (~10%): Primarily cholesterol.
• Surfactant-Associated Proteins (~10%):
  • SP-B and SP-C: Small, highly hydrophobic proteins essential for accelerating surfactant adsorption and monolayer spreading across the alveolar interface. Complete congenital SP-B deficiency is a rare autosomal recessive disorder that often causes severe neonatal respiratory failure; phenotype and response vary with the mutation.
  • SP-A and SP-D: Large, hydrophilic collectin proteins that participate in innate pulmonary defense, pathogen opsonization, and regulation of surfactant homeostasis.

The mechanical behavior of the terminal respiratory unit is governed by the Law of Laplace for a spherical air-liquid interface:

$P = \frac{2\gamma}{r}$

Where:

• $P$ is the distending (collapsing) pressure across the alveolar wall,
• $\gamma$ (or $T$) is the surface tension at the air-liquid interface, and
• $r$ is the alveolar radius.

+-------------------------------------------------------------------------------------------------------------+
|                                 THE LAW OF LAPLACE IN ALVEOLAR MECHANICS                                     |
+-------------------------------------+-----------------------------------------------------------------------+
| Without Surfactant                  | Surface tension (gamma) remains constant at ~70 dynes/cm.             |
| (Preterm RDS)                       | As radius (r) decreases during expiration, collapsing pressure (P)    |
|                                     | rises exponentially. Small alveoli empty into larger ones             |
|                                     | (Laplace instability), causing diffuse microatelectasis.             |
+-------------------------------------+-----------------------------------------------------------------------+
| With Surfactant                     | As alveolar radius decreases during expiration, DPPC molecules crowd  |
| (Term Normal Lung)                  | together, driving surface tension (gamma) near zero (~0-5 dynes/cm).  |
|                                     | Collapsing pressure remains low even at small volumes, preventing     |
|                                     | end-expiratory alveolar collapse and stabilizing Functional           |
|                                     | Residual Capacity (FRC).                                              |
+-------------------------------------+-----------------------------------------------------------------------+

Pathophysiological Cascade of Surfactant Deficiency

1. Diffuse Microatelectasis & Loss of FRC: High surface tension produces progressive end-expiratory alveolar collapse. Lung compliance ($C_L$) plummets, requiring enormous negative inspiratory pleural pressures to reopen collapsed units.
2. Severe Ventilation-Perfusion ($\dot{V}/\dot{Q}$) Mismatch & Intrapulmonary Shunting: Blood perfusing non-aerated, collapsed alveolar capillaries cannot participate in gas exchange. This creates a large true right-to-left intrapulmonary shunt that is refractory to supplemental oxygen alone.
3. Hypoxemia, Hypercapnia, and Mixed Acidosis: Impaired alveolar ventilation leads to carbon dioxide retention (respiratory acidosis), while tissue hypoxemia stimulates anaerobic glycolysis and lactic acid accumulation (metabolic acidosis).
4. Pulmonary Vasoconstriction & Extrapulmonary Shunting: Alveolar hypoxia and systemic acidemia provoke profound pulmonary arteriolar vasoconstriction, dramatically elevating Pulmonary Vascular Resistance (PVR). Suprasystemic PVR maintains right-to-left extrapulmonary shunting across the patent ductus arteriosus (PDA) and patent foramen ovale (PFO), establishing a self-perpetuating cycle of hypoxemia.
5. Epithelial/Endothelial Injury & Hyaline Membrane Formation: Cyclic reopening of collapsed alveoli and high shear stress damage capillary endothelium and alveolar epithelium. Plasma transudate rich in fibrin, cellular debris, and red blood cells leaks into the alveolar spaces, organizing within 12 to 24 hours into classic eosinophilic hyaline membranes that inactivate remaining surfactant stores.

Clinical Risk & Protective Factors

Clinical Manifestations

Signs of RDS usually begin at birth or during the first hours. The course depends on gestational age, antenatal therapy, surfactant, respiratory support, infection, air leak, and other complications rather than a guaranteed 48- to 72-hour peak:

• Tachypnea: Respiratory rate consistently exceeding $60\text{ breaths/min}$ as the infant attempts to compensate for a reduced tidal volume with rapid, shallow breathing.
• Expiratory Grunting: The hallmark protective reflex of RDS. The neonate partially closes the vocal cords (glottis) during expiration, creating dynamic backpressure. This auto-PEEP prevents end-expiratory alveolar collapse and preserves FRC.
• Thoracic Retractions: Intercostal, subcostal, and substernal retractions occur because the highly compliant, cartilaginous neonatal chest wall is drawn inward by the massive negative intrapleural pressures required to inflate non-compliant, stiff lungs.
• Nasal Flaring: Dilator naris contraction lowers upper airway resistance by up to 20%.
• Central Cyanosis: Reflects unoxygenated hemoglobin resulting from intrapulmonary and extrapulmonary right-to-left shunting.
• Auscultation: Diminished breath sounds bilaterally with fine, end-inspiratory crackles.

Radiographic Features of RDS

Chest radiography demonstrates a diagnostic triad:

1. Diffuse Reticulogranular Infiltrates: A uniform, fine 'ground-glass' appearance caused by widespread microatelectasis interspersed with small aerated alveolar ducts.
2. Prominent Air Bronchograms: Lucent, air-filled conducting bronchi visualized in sharp contrast against the surrounding opacified, collapsed alveolar parenchyma.
3. Hypoaeration (Low Lung Volumes): Small lung volumes resulting in a classic bell-shaped thorax with the diaphragmatic domes elevated above the 8th posterior rib.

---

Evidence-Based Management of RDS

Antenatal Corticosteroid Prophylaxis

Antenatal corticosteroids reduce RDS and other complications when preterm birth is likely and obstetric eligibility criteria are met:

• Recommended Regimen: Betamethasone 12 mg IM, administered as two doses 24 hours apart (or Dexamethasone 6 mg IM every 12 hours for 4 doses).
• Eligibility window: Common obstetric guidance recommends a course when preterm delivery within 7 days is likely in the principal preterm window and considers selected earlier or late-preterm patients. Gestational limits, prior courses, membrane status, diabetes, and contraindications follow the current obstetric protocol.
• Mechanism: Transplacental crossing activates fetal glucocorticoid receptors, inducing enzymes that catalyze phospholipid synthesis and accelerating structural thinning of the alveolar-capillary septum.

Delivery Room Noninvasive Respiratory Support

Modern neonatal resuscitation emphasizes the immediate preservation of lung architecture over routine invasive intubation:

• Early CPAP: For a spontaneously breathing preterm infant who needs respiratory support, CPAP is commonly started around $5\text{ to }7\text{ cmH}_2\text{O}$ with an appropriate nasal interface and titrated to response. Apnea, gasping, or bradycardia calls for effective ventilation rather than CPAP alone.
• Clinical Benefit: Early CPAP maintains FRC, prevents alveolar collapse at end-expiration, conserves endogenous surfactant stores, and significantly reduces the incidence of Bronchopulmonary Dysplasia (BPD) compared to routine prophylactic endotracheal intubation.

Exogenous Surfactant Replacement Therapy

Animal-derived surfactant preparations are the commonly used products in current neonatal practice; select the preparation and regimen from the product label and neonatal protocol:

• Preparations:
  • Poractant alfa (Curosurf): Porcine-derived; initial dose $200\text{ mg/kg}$ ($2.5\text{ mL/kg}$), subsequent doses $100\text{ mg/kg}$. Offers rapid onset and lower mortality.
  • Calfactant (Infasurf): Bovine calf lung extract; dose $105\text{ mg/kg}$ ($3.0\text{ mL/kg}$). Contains higher SP-B concentrations.
  • Beractant (Survanta): Bovine lung extract supplemented with DPPC; dose $100\text{ mg/kg}$ ($4.0\text{ mL/kg}$). Must be divided into aliquots.
• Indications: Consider early rescue surfactant for a preterm infant with worsening RDS despite optimized CPAP. Gestational age, oxygen trajectory, work of breathing, gas exchange, imaging, and the unit pathway determine the threshold; many protocols use an $FiO_2$ near 0.30 as one trigger, not an isolated universal rule.
• Administration Techniques:
  • LISA / MISA (Less/Minimally Invasive Surfactant Administration): Surfactant is instilled through a thin catheter placed through the vocal cords while the infant remains spontaneously breathing on CPAP. This can reduce exposure to invasive ventilation, but apnea, desaturation, reflux, bradycardia, or rescue intubation can still occur.
  • INSURE (INtubate-SURfactant-Extubate): Tracheal intubation, bolus surfactant delivery with brief manual/mechanical ventilation, followed by rapid extubation back to CPAP within 15 to 60 minutes.

---